Table 2.
The effect of eucalyptol on glycation, oxidative stress and inflammatory markers as well as activity of glyoxalase-I in the normal (N) and diabetic-atherosclerotic rats (D)
| Parameters | Groups | |||
|---|---|---|---|---|
| N | N (Eucalyptol) | D | D (Eucalyptol) | |
| Glycated LDL (µmol/l) | 60.25±2.34 | 58.43±2.65 | 173.98±8.09N | 128.16±6.90N,D |
| Methylglyoxal (µmol/l) | 17.45±1.36 | 9.64±0.83N | 155.31±8.61N | 69.42±3.75N,D |
| Early LDL oxidation products (µmol/l) | 20.43±1.34 | 18.65±0.97 | 87.65±5.03N | 47.45±3.66N,D |
| End LDL oxidation products (µmol/l) | 254.43±17.98 | 247.65±15.09 | 487.16±23.09N | 403.73±19.12N,D |
| Advanced oxidation protein products (µmol/l) | 30.71±4.08 | 26.32±3.95 | 89.65±6.01N | 48.74±375N,D |
| Malondialdehyde (µmol/l) | 9.84±0.62 | 9.96±0.73 | 101.57±7.36N | 80.82±5.54N,D |
| Glutathione (µmol/l) | 188.15±9.03 | 192.67±10.67 | 99.43±5.05N | 139.81±7.33N,D |
| Tumor necrosis factor-α (pg/ml) | 131.54±8.12 | 100.06±6.23N | 321.76±18.06N | 245.22±14.81N,D |
| Glyoxalase-I (U/ml) | 39.95±4.64 | 47.68±2.92N | 20.85±3.05N | 35.16±3.37N,D |
NIndicates significance of data comparing normal group (N) with other groups (P<0.001). DIndicates significance of data comparing diabetic-atherosclerotic group (D) with other groups (P<0.001). LDL: Low-density lipoprotein